Medical Affairs, Shionogi & Co., Ltd, Osaka, Japan.
Milliman Inc., Tokyo, Japan.
J Med Econ. 2022 Jan-Dec;25(1):38-50. doi: 10.1080/13696998.2021.2012073.
To estimate the cost of antiviral medication guidance and/or support from the perspective of healthcare professionals by administration route (oral or inhalant).
An online survey (December 2020) was conducted among physicians, pharmacists, and certified care workers. Those aged 20-64 years working in workplaces with experience of prescribing (physicians) or dispensing (pharmacists) antivirals for influenza, or having care service recipients who took antivirals (certified care workers) since October 2018, were selected through screening questions. The time required for guidance and/or support for drug administration was asked, and its monetary value was calculated by applying the Japanese average wage. Respondents who had a fear of infection while providing guidance and/or support were asked about the monetary value of this fear; the cost of fear was estimated from their responses and the percentage who reported such a fear.
Responses were collected from 1,000 physicians, 1,000 pharmacists, and 642 certified care workers. The cost of the time for guidance and/or support in the entire workplace was estimated as JPY 244 (USD 2.14, as of October 2021) for oral antivirals and JPY 289 for inhalants among physicians, JPY 260 and JPY 428 among pharmacists, and JPY 555 and JPY 557 among certified care workers. The cost of fear was estimated to be JPY 965 for oral and JPY 1,361 for inhalants among physicians, JPY 756 and JPY 2,711 among pharmacists, and JPY 2,419 and JPY 2,837 among certified care workers.
Respondents might not be representative of Japanese society. The reliability of the results depends on whether the respondents accurately understood the questions and their truthfulness.
Higher costs for guidance and/or support were suggested for inhalant antivirals in physicians and pharmacists compared to oral antivirals. For certified care workers, almost no difference in costs was suggested between administration routes.
通过给药途径（口服或吸入），从医疗保健专业人员的角度估算抗病毒药物指导和/或支持的成本。
2020 年 12 月，对医生、药剂师和认证护理人员进行了在线调查。通过筛选问题，选择了年龄在 20-64 岁之间，在工作场所具有开具（医生）或配药（药剂师）流感抗病毒药物经验，或自 2018 年 10 月以来有接受抗病毒药物治疗的护理服务接受者（认证护理人员）的人员。询问了指导和/或支持药物给药所需的时间，并用日本平均工资计算其货币价值。对于在提供指导和/或支持时感到感染恐惧的受访者，询问了这种恐惧的货币价值；根据他们的回答和报告这种恐惧的百分比来估计恐惧的成本。
共收到 1000 名医生、1000 名药剂师和 642 名认证护理人员的回复。在整个工作场所，医生指导和/或支持的时间成本估计为口服抗病毒药物 244 日元（2021 年 10 月为 2.14 美元），吸入剂为 289 日元；药剂师分别为 260 日元和 428 日元；认证护理人员分别为 555 日元和 557 日元。对于口服和吸入抗病毒药物，医生的恐惧成本估计为 965 日元，药剂师的恐惧成本估计为 756 日元和 2711 日元；认证护理人员的恐惧成本估计分别为 2419 日元和 2837 日元。
受访者可能无法代表日本社会。结果的可靠性取决于受访者是否准确理解问题及其真实性。
与口服抗病毒药物相比，医生和药剂师认为吸入性抗病毒药物的指导和/或支持成本更高。对于认证护理人员，两种给药途径的成本差异不大。
Zotero 插件